



# Corporate Presentation

Helping Minds Heal

January 5, 2026

Nasdaq: HELP  
Cboe CA: HELP

# Cautionary Statement

The information contained in this presentation has been prepared by Cybin Inc. and its affiliates ("Cybin" or the "Company"), which operates as Helus Pharma and its respective affiliates. The information contained in this presentation: (a) is provided as at the date hereof, is subject to change without notice, and is based on publicly available information, internally developed data and third party information from other sources; (b) does not purport to contain all the information that may be necessary or desirable to fully and accurately evaluate an investment in the Company; (c) is not to be considered as a recommendation by the Company that any person make an investment in the Company; and (d) is for information purposes only and shall not constitute an offer to buy, sell, issue or subscribe for, or the solicitation of an offer to buy, sell or issue, or subscribe for any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. Where any opinion or belief is expressed in this presentation, it is based on certain assumptions and limitations and is an expression of present opinion or belief only. The third-party information has not been independently verified. While the Company may not have verified the third-party information, it believes that it obtained the information from reliable sources and has no reason to believe it is not accurate in all material respects. No warranties or representations can be made as to the origin, validity, accuracy, completeness, currency or reliability of the information. Cybin disclaims and excludes all liability (to the extent permitted by law), for losses, claims, damages, demands, costs and expenses of whatever nature arising in any way out of or in connection with the information in this presentation, its accuracy, completeness or by reason of reliance by any person on any of it. This presentation should not be construed as legal, financial or tax advice to any individual, as each individual's circumstances are different. Readers should consult with their own professional advisors regarding their particular circumstances. In making an investment decision, investors should not rely solely on the information contained in this presentation. The delivery of this presentation, at any time, will not imply that the information contained in the presentation is correct as of any time subsequent to the date set forth on the cover page of the presentation or the date at which such information is expressed to be stated, as applicable. No securities commission, exchange or similar regulatory authority in Canada or the United States has reviewed or in any way opined on the merits of this presentation, and any representation to the contrary is an offence.

Certain statements in this presentation constitute forward-looking information or forward-looking statements, within the meaning of applicable securities legislation (together, "forward looking statements"). All statements, other than statements of historical fact contained in this presentation, including, without limitation, statements regarding Cybin's future, strategy, plans, objectives, goals and targets, and any statements preceded by, followed by or that include the words "believe", "expect", "aim", "intend", "plan", "continue", "will", "may", "would", "anticipate", "estimate", "forecast", "predict", "project", "seek", "should" or similar expressions or the negative thereof, are forward-looking statements. These statements are not historical facts but instead represent only Cybin's expectations, estimates and projections regarding future events. These statements are not guaranteeing future performance and they involve assumptions, risks and uncertainties that are difficult to predict. Therefore, actual results may differ materially from what is expressed, implied or forecasted in such forward-looking statements.

Forward-looking statements are based on a number of factors and assumptions made by management and considered reasonable at the time such information is provided, and forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Risk Factors that could cause actual results, performance or achievement to differ materially from those indicated in the forward-looking statements include, but are not limited to the following: regulatory, legislative, legal or other developments with respect to its operations or business; general economic conditions and financial markets; the loss of key management personnel; capital requirements and liquidity; access to capital; the timing and amount of capital expenditures; the impact of disease outbreaks; conflicts of interest; uninsurable risks; and litigation and other factors beyond the Company's control. Readers are cautioned that the foregoing list and the risk factors under the heading "Risk Factors" are not exhaustive. The forward-looking information and forward-looking statements included in this presentation are made as of the date of this presentation. The Company does not undertake any obligation to update such forward-looking statements or forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities law. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date. Third party information has not been independently verified. No warranties or representations can be made as to the origin, validity, accuracy, completeness, currency or reliability of the information.

## RISK FACTORS

There are a number of risk factors that could cause future results to differ materially from those described herein. A discussion of the principal risk factors relating to the Company's operations and business appear in the Company's most recently filed management's discussion and analysis and the annual information form, which are available under the Company's profile on [www.sedarplus.ca](http://www.sedarplus.ca) and with the United States Securities and Exchange Commission on EDGAR at [www.sec.gov](http://www.sec.gov). Additional risks and uncertainties, including those that the Company is not aware of currently, or that it currently deems immaterial, may also adversely affect the Company's business or any investment therein. All of the forward-looking statements made in this presentation are qualified by these cautionary statements and other cautionary statements or other factors contained herein. Although management believes that the expectations conveyed by forward-looking statements herein are reasonable based on information available on the date such forward-looking statements are made, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. The forward-looking statements contained herein are presented for the purposes of assisting readers in understanding the Company's plan, objectives and goals and may not be appropriate for other purposes. The reader is cautioned not to place undue reliance on forward-looking statements.

## CAUTIONARY NOTE REGARDING FUTURE-ORIENTED FINANCIAL INFORMATION

To the extent that any forward-looking statement in this presentation constitutes "future-oriented financial information" or "financial outlooks" within the meaning of applicable securities laws, such information is being provided to demonstrate the anticipated market penetration and the reader is cautioned that this information may not be appropriate for any other purpose and the reader should not place undue reliance on such future-oriented financial information and financial outlooks. Future-oriented financial information and financial outlooks, as with forward-looking statements generally, are, without limitation, based on the assumptions and subject to the risks set out above under the heading "Cautionary Statement Regarding Forward-Looking Information". The Company's actual financial position and results of operations may differ materially from management's current expectations and, as a result, the Company's revenue and expenses.

## CAUTIONARY NOTE REGARDING REGULATORY MATTERS

The Company conducts research and development and is focused on developing and commercializing therapeutics are regulated as controlled substances in certain jurisdictions, including Canada, Ireland, The United Kingdom, The United States, and certain of the states and provinces therein. For these reasons, the Company may be (a) subject to heightened scrutiny by regulators, stock exchanges, clearing agencies and other authorities, (b) susceptible to regulatory changes or other changes in law, and (c) subject to risks related to drug development, among other things, including a possibility such scheduling or laws would need to change for the Company to commercialize certain of its proposed products. The Company makes no medical, treatment or health benefit claims about the Company's proposed products, nor have any regulatory authorities approved such proposed products. The efficacy of such products has not been confirmed by approved research. If the Company cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company's performance and operations.

## DRUG DEVELOPMENT

Drug development involves long lead times, is very expensive and involves many variables of uncertainty. There is no assurance that any timelines estimated herein will be met. Anticipated timelines regarding drug development are based on reasonable assumptions informed by current knowledge and information available to the Company. This presentation contains certain forward-looking statements regarding anticipated or possible drug development timelines. Such statements are informed by, among other things, regulatory guidelines for developing a drug with safety studies, proof of concept studies, and pivotal studies for new drug application submission and approval, and assumes the success of implementation and results of such studies on timelines indicated as possible by such guidelines, other industry examples, and the Company's development efforts to date.

## INDUSTRY INFORMATION

This presentation also contains or references certain market, industry and peer group data which is based upon information from independent industry publications, market research, analyst reports and surveys and other publicly available sources. Although the Company believes these sources to be generally reliable, such information is subject to interpretation and cannot be verified with complete certainty due to limits on the availability and reliability of data, the voluntary nature of the data gathering process and other inherent limitations and uncertainties. The Company has not independently verified any of the data from third party sources referred to in this presentation and accordingly, the accuracy and completeness of such data is not guaranteed.

## US DISCLAIMER

This corporate overview is not a prospectus or an offering memorandum pursuant to applicable United States securities laws. The securities of Cybin may not be offered or sold in the "United States", or to, or for the account or benefit of, "U.S. persons" as such terms are defined in Regulation S under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), unless pursuant to the registration requirements of the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements. The securities of Cybin have not been approved or disapproved by the United States Securities and Exchange Commission, or any other securities commission or regulatory authority in the United States, nor have any of the foregoing authorities passed upon or endorsed the merits of any of the securities of Cybin nor have they approved this presentation or confirmed the accuracy or adequacy of the information contained in this presentation. Any representation to the contrary is a criminal offense.

# Leading the Development of Novel Serotonergic Agonists (NSAs)<sup>1,2</sup>

- 1 Two proprietary clinical programs, HLP003 and HLP004, targeting major depressive disorder ("MDD") and generalized anxiety disorder ("GAD") with positive Phase 2 safety and efficacy results
- 2 Lead program HLP003 has been granted U.S. Food and Drug Administration Breakthrough Therapy Designation and is in Phase 3 studies for the adjunctive treatment of MDD
- 3 Differentiated pipeline with potential for expansion into additional mental health indications with high unmet need affecting >200M people in the U.S.<sup>3</sup>
- 4 Strong Intellectual Property Portfolio over 100 granted patents, over 250 patent applications pending
- 5 Cash position of US\$83.8 million (September 30, 2025)  
Completed US\$175 million registered direct offering in October 2025

Notes:

1) Novel serotonergic agonists (NSAs): synthetic molecules designed to activate serotonin pathways that are believed to drive neuroplasticity.

2) Forward looking statements are subject to risks and assumptions. See "Cautionary Statement" on page 2 of this presentation. There is no assurance that timelines will be met. Anticipated timelines regarding drug development are based on reasonable assumptions informed by current knowledge and information available to Helus. Such statements are informed by, among other things, regulatory guidelines for developing a drug with timeline safety studies, proof of concept studies, and pivotal studies for new drug application submission and approval, and assumes the success of implementation and results of such studies on timelines indicated as possible by such guidelines, other industry examples, and Helus's development efforts to date.

3) Addressable market is estimated based on U.S. census population of 337,049,203 as of September 8, 2024 and on U.S. prevalence of indications including depression, anxiety disorders/PTSD, bipolar disorder, substance use/addiction disorders, eating disorders, cluster headaches/migraine, and chronic pain management.

# Leadership Team with Proven Record of Regulatory & Commercial Success



**Eric So**  
Interim Chief  
Executive Officer



**Amir Inamdar MBBS,  
DNB(Psych), FFPM**  
Chief Medical Officer



**Alex Nivorozhkin, Ph.D.**  
Chief Scientific Officer



**Aaron Bartlone**  
Chief Operating Officer



**George Tzirias**  
Chief Business Officer



**Paul Glavine**  
Co-Founder & Chief  
Growth Officer



**Allison  
House-Gecewicz**  
SVP, Clinical Operations



**Atul R. Mahableshwarkar,  
M.D., DLFAPA**  
SVP, Clinical Development



**Robert Mino JD, MBA, MS**  
General Counsel & IP Counsel



**Tom Macek Ph.D.**  
SVP, Clinical Development



**Kenneth Avery Ph.D.**  
SVP Chemistry & Manufacturing



**Geoff Varty Ph.D.**  
SVP, Research &  
Pre-Clinical Development



**Peter Kratochvila**  
VP, Regulatory

# Executing on Our Innovative Pipeline to Enable a Paradigm Shift in Mental Health

PROGRAM	INDICATION	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3	NEXT MILESTONES <sup>1,2,3</sup>
<b>HLP003</b> Deuterated NSA (Oral)	Adjunctive treatment of MDD	Phase 3 study dosing underway Granted FDA Breakthrough Therapy Designation				<b>Q4 2026:</b> Phase 3 APPROACH topline data
<b>HLP004</b> Deuterated NSA (Intramuscular)	GAD	Phase 2 study enrollment complete				<b>Q1 2026:</b> Phase 2 topline data
<b>HLP005</b> Phenethylamines and Tryptamines	Central Nervous System (CNS) Disorders	Preclinical studies				

Notes:

- Forward-looking statements are subject to risks and assumptions. See "Cautionary Statement" on page 2 of this presentation.
- Subject to receipt of all necessary regulatory approvals from all applicable governmental authorities, including, as applicable, the academic and scientific organizations with which Helus is working. There are multiple risk factors regarding the ability to successfully commercially scale a chemically synthesized process to obtain psilocin and other analogues. There is no assurance that timelines will be met. Anticipated timelines regarding drug development are based on reasonable assumptions informed by current knowledge and information available to Helus. Such statements are informed by, among other things, regulatory guidelines for developing a drug with timeline safety studies, proof of concept studies, and pivotal studies for new drug application submission and approval, and assumes the success of implementation and results of such studies on timelines indicated as possible by such guidelines, other industry examples, and Helus's development efforts to date.
- Helus is prioritizing the progression of its HLP003 program. The advancement of Helus's HLP004, HLP005 and technology programs are all contingent on Helus's ability to continue raising capital under its current and future financing arrangements. No assurances can be given that Helus will be able to raise the additional capital that it may require for its anticipated future development.

# MDD and GAD: Leading Contributors to Mental Health Patient Burden

	Addressable Market	Health Impact	Need for Improved Treatments
HLP003 MDD	<p>&gt;300 million people worldwide<sup>1</sup></p> <p>21 million with MDD in the U.S.<sup>2</sup></p>	<ul style="list-style-type: none"> <li>• Suicide risk is 20x higher for an individual with vs. without depression<sup>3</sup></li> <li>• 50-75% of MDD patients also have anxiety symptoms<sup>4</sup></li> </ul>	<ul style="list-style-type: none"> <li>• 2/3rds of patients do not experience relief with initial antidepressant treatment<sup>5</sup></li> <li>• SSRI/SNRI* side effects: weight gain (18%)<sup>6</sup>, sexual dysfunction (up to 30%)<sup>7</sup>, GI disturbances<sup>16</sup> and insomnia (25%)<sup>8</sup></li> </ul>
HLP004 GAD	<p>&gt;300 million people with anxiety disorders worldwide<sup>10</sup></p> <p>20 million with GAD in the U.S.<sup>11</sup></p>	<ul style="list-style-type: none"> <li>• GAD is the most common anxiety disorder seen in primary care<sup>12</sup></li> <li>• GAD patients represent ~45% of total patient volume in interventional psychiatry practices and are a significant burden to treatment time<sup>15</sup></li> <li>• ~77% of adults with GAD have moderate to severe impairment<sup>13</sup></li> </ul>	<ul style="list-style-type: none"> <li>• With 2<sup>nd</sup> and 3<sup>rd</sup> line treatments, efficacy decreases; intolerance and relapse rates increase<sup>9</sup></li> <li>• 50% of patients with GAD do not respond to first line treatment with SSRIs and SNRIs<sup>12</sup></li> <li>• 57% of patients with anxiety do not adhere to SSRI/SNRIs, due to side effects<sup>14</sup></li> </ul>

Notes:

1-16: See references on slide 24.


\*SSRI = Selective serotonin reuptake inhibitor, SNRI = Serotonin-norepinephrine reuptake inhibitor.

# Portfolio strategy expands addressable market and commercial opportunity<sup>5,6</sup>

Broaden addressable market & address comorbidities

Leverage portfolio and drive commercial synergies

Addressing overlapping needs in MDD and GAD



## HLP003 Build


- Salesforce and distribution network
- Reimbursement and contracting framework

## HLP004 Leverage Economies of Scale

- Contracting
- Salesforce share-of-voice

# Strong IP Portfolio Supporting HLP003 and HLP004<sup>1,2,3</sup>

## U.S. Exclusivity Timeline



### ✓ Multilayered IP strategy

- Compositions and:
  - Oral Dosage Forms – HLP003
  - Injectable Formulations – HLP004
- Focused formulations
- Salt / crystalline forms
- Methods of treatment supported by positive clinical data

✓ **Issued patents** provide IP protection until at least **2041**

✓ Continued focus on patent lifecycle


✓ Protection of additional program IP as well as other NSAs

#### Notes:

- 1) "Granted Patent Exclusivity" dates are based on issued patents and assume maintenance fee payments, with no early termination or invalidation. "Pending Protection" reflects anticipated IP rights; issuance and scope are not guaranteed. Patent and exclusivity terms vary by jurisdiction and are subject to change. "NCE Exclusivity" refers to U.S. FDA regulatory exclusivity under the Hatch-Waxman Act and is an estimate only. Data exclusivity is distinct from patent protection and may provide additional market exclusivity. All dates are estimates and subject to legal, regulatory, or commercial developments.
- 2) Subject to receipt of all necessary regulatory approvals from all applicable governmental authorities, including, as applicable, the academic and scientific organizations with which Helus is working. There are multiple risk factors regarding the ability to successfully commercially scale a chemically synthesized process to obtain psilocin and other analogues. There is no assurance that timelines will be met. Anticipated timelines regarding drug development are based on reasonable assumptions informed by current knowledge and information available to Helus. Such statements are informed by, among other things, regulatory guidelines for developing a drug with timeline safety studies, proof of concept studies, and pivotal studies for new drug application submission and approval, and assumes the success of implementation and results of such studies on timelines indicated as possible by such guidelines, other industry examples, and Helus's development efforts to date.
- 3) Forward-looking statements are subject to risks and assumptions. See "Cautionary Statement" on page 2 of this presentation.



# Why Adjunctive Treatment Matters in MDD



## Benefits of adjunctive treatment:

- ✓ Begin treatment immediately
- ✓ Prevent withdrawal symptoms
- ✓ Remove barriers to treatment transition
- ✓ Build on benefits of background medications

## Expansion potential into adjacent behavioral disorders<sup>4</sup>

Indications with early supporting studies	U.S. Prevalence	Estimated Addressable Market
Anxiety Disorders / PTSD	19.1%/ 3.6%	64/12 million
Substance Use / Addiction Disorders	14.5%	48 million
Eating Disorders	0.3-1.2%	1-4 million
<b>Total</b>		<b>~115 million</b>

### Notes:

- <https://www.nimh.nih.gov/health/statistics/major-depression>
  - Vasiliadis, H. M., Lesage, A., Adair, C., Wang, P. S., & Kessler, R. C. (2007). Do Canada and the United States differ in prevalence of depression and utilization of services?. *Psychiatric services* (Washington, D.C.), 58(1), 63-71. <https://doi.org/10.1176/ps.2007.58.1.63>
  - Sinyor, M., Schaffer, A., & Levitt, A. (2010). The sequenced treatment alternatives to relieve depression (STAR\*D) trial: a review. *Canadian journal of psychiatry*, 55(3), 126-135. <https://doi.org/10.1177/070674371005500303>
  - Regier, Darrel J., et. al., DSM-5 Field Trials in the United States and Canada, Part II: Test-Retest Reliability of Selected Categorical Diagnoses October 2012. *American Journal of Psychiatry* 170(1)
  - Luo et al. (2020). National Prescription Patterns of Antidepressants in the Treatment of Adults With Major Depression in the U.S. Between 1996 and 2015: A Population Representative Survey Based Analysis. *Frontiers in Psychiatry* 11.
- \*SSRI = Selective serotonin reuptake inhibitor, SNRI = Serotonin-norepinephrine reuptake inhibitor

# Reducing Burden on Clinical Infrastructure

Interventional Psychiatry Clinics have been growing in the U.S.

Approximately 8,000 existing Interventional Psychiatry clinics with capacity


- 5300 SPRAVATO®<sup>1</sup> clinics
- 750 ketamine-only clinics<sup>2</sup>
- 2,300 TMS clinics<sup>3</sup>

Infrastructure to support uptake of HLP003 will exist in all types of Interventional Psychiatry clinics

Partnership with **osmind**<sup>4</sup>:

- Leverage extensive network of >800 psychiatry clinics in the U.S
- Strengthen expertise in logistics, clinical workflows and reimbursement pathways

HLP003 offers the opportunity to significantly reduce treatment burden



# HLP003

Deuterated Oral NSA  
Adjunctive Treatment of MDD

# HLP003 Program Overview

- U.S. FDA Breakthrough Therapy Designation for adjunctive treatment of MDD
- Dosing underway in Phase 3 PARADIGM program
- Next milestone: Initiation of enrollment in second pivotal study, EMBRACE, in Q4 2025<sup>1,2,3</sup>

## Positive 12-month Phase 2 Results in MDD (2 doses – 16 mg)

### Sustained improvements in depression symptoms

- Mean ~23-point reduction in Montgomery-Asberg Depression Rating Scale (MADRS) scores from baseline at 12 months (average baseline MADRS was ~32) following 2 doses of HLP003 16 mg

### Durable response and remission rates

- 100% of 16 mg patients receiving 2 doses were responders at 12 months
- 71% of 16 mg patients receiving 2 doses were in remission at 12 months


### Favorable safety and tolerability profile

- All reported adverse events (“AEs”) mild to moderate; no AEs of suicidality
- No AEs/serious adverse events (“SAEs”) reported in the 12-month follow up

#### Notes:

- <sup>1</sup> Forward-looking statements are subject to risks and assumptions. See “Cautionary Statement” on page 2 of this presentation.
- <sup>2</sup> Subject to receipt of all necessary regulatory approvals from all applicable governmental authorities, including, as applicable, the academic and scientific organizations with which Helus is working. There are multiple risk factors regarding the ability to successfully commercially scale a chemically synthesized process to obtain psilocin and other analogues, authorities, including, as applicable, the academic and scientific organizations with which Helus is working. There are multiple risk factors regarding the ability to successfully commercially scale a chemically synthesized process to obtain psilocin and other analogues. There is no assurance that timelines will be met. Anticipated timelines regarding drug development are based on reasonable assumptions informed by current knowledge and information available to Helus. Such statements are informed by, among other things, regulatory guidelines for developing a drug with timeline safety studies, proof of concept studies, and pivotal studies for new drug application submission and approval, and assumes the success of implementation and results of such studies on timelines indicated as possible by such guidelines, other industry examples, and Helus’s development efforts to date.
- <sup>3</sup> Helus is prioritizing the progression of its HLP003 program. The advancement of Helus’s HLP004, HLP005 and technology programs are all contingent on Helus’s ability to continue raising capital under its current and future financing arrangements. No assurances can be given that Helus will be able to raise the additional capital that it may require for its anticipated future development.

# Large Improvement in Depression Symptoms After Single Dose of HLP003<sup>1</sup>





Dose <sup>1</sup>	Primary Endpoint*	Effect size	p-value
12 mg	-14.11	2.31	0.0001
16 mg	-12.99	2.54	0.0080

\*Primary endpoint: difference in change from baseline in MADRS total score between HLP003 and placebo at 3 weeks

Note:

1) Data based on patients who received at least one dose of HLP003 and have at least one post-baseline MADRS assessment.

# HLP003: Sustained Improvements in Depression Symptoms at 12 Months<sup>1</sup>



Note:  
1) Data based on post-hoc analysis of patients who received two doses of 16 mg of HLP003 and participated in long-term extension study.

# Phase 3 PARADIGM Program Overview

Study design aligned with FDA guidance and two meetings with FDA

Addressing functional unblinding

Phase 3 underway


The pivotal program will consist of 2 studies plus an extension<sup>1,2,3</sup>:

- APPROACH: Two-arm study of two 16 mg doses of HLP003 vs. placebo
- EMBRACE: Three-arm study with two 16 mg doses, 8 mg doses, and a placebo arm
- EXTEND: Long-term extension study to confirm durability of effect, time to redosing and frequency of redosing for participants who did not respond in the first two studies or relapsed during the extension study
- Use of remote, independent, blinded raters
- Dosing session procedural safeguards designed to prevent functional unblinding
- Long-term efficacy data points up to one year to outlast expectancy bias
- Multinational Phase 3 program will include more than 100 sites across the U.S., Europe and Australia<sup>1,2,3</sup>
- Study sites selected with clinical expertise and training in depression studies
- Clinical supplies manufactured and ready

Notes:

- 1) Forward-looking statements are subject to risks and assumptions. See "Cautionary Statement" on page 2 of this presentation.
- 2) Subject to receipt of all necessary regulatory approvals from all applicable governmental authorities, including, as applicable, the academic and scientific organizations with which Helus is working. There are multiple risk factors regarding the ability to successfully commercially scale a chemically synthesized process to obtain psilocin and other analogues. There is no assurance that timelines will be met. Anticipated timelines regarding drug development are based on reasonable assumptions informed by current knowledge and information available to Helus. Such statements are informed by, among other things, regulatory guidelines for developing a drug with timeline safety studies, proof of concept studies, and pivotal studies for new drug application submission and approval, and assumes the success of implementation and results of such studies on timelines indicated as possible by such guidelines, other industry examples, and Helus's development efforts to date.
- 3) Helus is prioritizing the progression of its HLP003 program. The advancement of Helus's HLP004, HLP005 and technology programs are all contingent on Helus's ability to continue raising capital under its current and future financing arrangements. No assurances can be given that Helus will be able to raise the additional capital that it may require for its anticipated future development.

# PARADIGM: HLP003 Phase 3 Pivotal Program in MDD



Phase 3 APPROACH topline data expected in Q4 2026<sup>3</sup>

## Notes:

- 1) Primary endpoint: MADRS change from baseline at 6 weeks.
- 2) Key secondary endpoint: MADRS change from baseline at 12 weeks.
- 3) Forward-looking statements are subject to risks and assumptions. There is no assurance that timelines will be met. Anticipated timelines regarding drug development are based on reasonable assumptions informed by current knowledge and information available to the Company. Such statements are informed by, among other things, regulatory guidelines for developing a drug with safety studies, proof of concept studies, and pivotal studies for new drug application submission and approval, and assume the success of implementation and results of such studies on timelines indicated as possible by such guidelines, other industry examples, and the Company's development efforts to date.



# HLP004

Deuterated Intramuscular NSA  
Treatment of GAD

# HLP004 Program Overview

## Short-duration treatment with convenient dosing

- Short-duration treatment
- Intramuscular dosing is more convenient and patient-friendly vs. IV and inhalation

## Demonstrated proof-of-concept in depression and anxiety

- Strong datasets across 5 clinical studies supporting characterization and dosing optimization
- Positive efficacy in depression with improvements in anxiety scores
- Favorable safety profile

## Robust IP Protection for Deuterated NSA

- >50 patents in support of HLP004 program

# Optimized Data from 5 Clinical Studies in the Development Program

## Completed Studies

- 1 Phase 1/2a study in moderate to severe MDD (no SSRIs)<sup>1</sup>
- 2 Phase 1 IV/IM study<sup>1</sup>
- 3 Phase 1 SSRI DDI study<sup>1</sup>
- 4 Phase 1 Study of IV HLP004 and IV non-deuterated analog
- 5 Phase 1 IM/IV dNSA<sup>2</sup> study<sup>3</sup>

## Key Findings

**Rapid and durable antidepressant and anxiolytic effect observed with non-deuterated analog of HLP004**

- ✓ 46% of MDD patients in remission at 3 months
- ✓ Among the patients that achieved remission at 3 months, 64% had sustained remission at 6 months
- ✓ 40% of MDD patients in remission at 6 months
- ✓ Rapid improvement in anxiety and wellbeing scores
- ✓ IV route safe and well-tolerated

**Characterized safe and well-tolerated IM route**

**Non-deuterated analog safe and well-tolerated when co-administered with SSRIs**

**Potential enhanced effect when given as adjunctive to SSRIs:**


- ✓ 92% remission rate in SSRI cohort vs. 20% remission (non-SSRI cohort)

Note:

- 1) Completed with SPL026, a non-deuterated analog of HLP004.
- 2) dNSA = deuterated novel serotonergic agonists.
- 3) Study completed with related dNSA, SPL028.

# Non-Deuterated Analog of HLP004 Demonstrates Proof-of-Concept in Reducing Anxiety Symptoms

- ✓ Efficacy assessed as change from baseline in STAI-T scores<sup>1</sup>
- ✓ Data from the MDD monotherapy (21.5 mg)<sup>2</sup> and SSRI add on studies (27.5 mg)<sup>2</sup>
- ✓ Provide proximal de-risking of development in anxiety




## Notes:

1) STAI: State-Trait Anxiety Inventory.

2) SPL026 is a non-deuterated analog of HLP004. Doses: 21.5 mg and 27.5 mg doses administered at different rates. 21.5 mg in the Phase 2a MDD study, 27.5 mg in the SSRI DDI study. Placebo data reported is from the Phase 2a study in MDD.

# HLP004 in GAD: Phase 2 Proof-of-Concept Study



- Moderate to severe GAD
- Concomitant antidepressant/anxiolytic treatment and co-morbid depression allowed

- Primary endpoint: HAM-A
- Other endpoints: HAM-D, safety, EQ-5D-5L

Phase 2 study enrollment complete; Topline data in Q1 2026<sup>1</sup>

Note:

1) Forward-looking statements are subject to risks and assumptions. See "Cautionary Statement" on page 2 of this presentation. Subject to receipt of all necessary regulatory approvals from all applicable governmental authorities, including, as applicable, the academic and scientific organizations with which Helus is working. There are multiple risk factors regarding the ability to successfully commercialize a chemically synthesized process to obtain psilocin and other analogues. Anticipated timelines regarding drug development are based on reasonable assumptions informed by current knowledge and information available to the Company.

# Value-Driving Milestones Across Development Pipeline<sup>1,2</sup>

Q1 2026

- Topline data readout from Phase 2 study of **HLP004** in GAD

Q4 2026

- Topline efficacy data readout from Phase 3 **APPROACH** study of **HLP003** in MDD

Notes:

- 1) Forward-looking statements are subject to risks and assumptions. See "Cautionary Statement" on page 2 of this presentation.
- 2) Subject to receipt of all necessary regulatory approvals from all applicable governmental authorities, including, as applicable, the academic and scientific organizations with which Helus is working. There are multiple risk factors regarding the ability to successfully commercially scale a chemically synthesized process to obtain psilocin and other analogues. Anticipated timelines regarding drug development are based on reasonable assumptions informed by current knowledge and information available to the Company.

# Thank You

Nasdaq: HELP | Cboe CA: HELP

Contact: [irteam@helus.com](mailto:irteam@helus.com)

# References

## SLIDE 6

1. World Health Organization. (2017). Depression and other common mental disorders: global health estimates. World Health Organization. <https://iris.who.int/handle/10665/254610>.
2. <https://www.nimh.nih.gov/health/statistics/major-depression>; Vasiliadis, H. M., Lesage, A., Adair, C., Wang, P. S., & Kessler, R. C. (2007). Do Canada and the United States differ in prevalence of depression and utilization of services?. *Psychiatric services (Washington, D.C.)*, 58(1), 63–71. <https://doi.org/10.1176/ps.2007.58.1.63>
3. American Association of Suicidology, 2014. <https://www.cga.ct.gov/asafcrconnecticut/tmy/0129/Some%20Facts%20About%20Suicide%20and%20Depression%20-%20Article.pdf>
4. Hopwood M. (2023). Anxiety Symptoms in Patients with Major Depressive Disorder: Commentary on Prevalence and Clinical Implications. *Neurology and therapy*, 12(Suppl 1), 5–12. <https://doi.org/10.1007/s40120-023-00469-6>
5. Little A. Treatment-resistant depression. *Am Fam Physician*. 2009;80:167–72.
6. Sussman et al. *J Clin Psychiatry*. 2001(Apr);62(4):256–260
7. Clayton AH, et al. *J Clin Psychiatry*. 2002 Apr;63(4):357–66.
8. Fava M, et al. *J Clin Psychopharmacol*. 2002;22(2):137–147.
9. Rush AJ et al. "Acute and longer-term outcomes in depressed outpatient requiring one or several treatment steps: A STAR\*D report". *The American Journal of Psychiatry*. 2006. 163(11):1905–1917. Diagram represents anticipated treatment outcomes as patients cycle through the current depression treatment guidelines
10. Yang et al. (2021). Global, regional and national burden of anxiety disorders from 1990 to 2019: results from the Global Burden of Disease Study 2019. *Epidemiology and Psychiatric Sciences* 30, e36, 1–11. <https://doi.org/10.1017/S2045796021000275/>
11. Ringeisen, H., et. al. (2023). Mental and Substance Use Disorders Prevalence Study (MDPS): Findings Report. RTI International.
12. Ansara E. D. (2020). Management of treatment-resistant generalized anxiety disorder. *The mental health clinician*, 10(6), 326–334. <https://doi.org/10.9740/mhc.2020.11.326>
13. Kessler et al. (2005). Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. *Arch Gen Psychiatry*, 62(6):617–27.
14. Stein et al. (2006). Antidepressant Adherence and Medical Resource Use Among Managed Care Patients With Anxiety Disorders. *Psychiatric Services*, 57(5): 673–680.
15. Helus proprietary quantitative HCP market research (n=60)
16. Gastrointestinal side effects associated with antidepressant treatments in patients with major depression disorder, Volume 109, July 13, 2021, *Progress in Neuro-Psychopharmacology and Biological Psychiatry* (110266)

## SLIDE 7

- 1) <https://www.nimh.nih.gov/health/statistics/major-depression>
- 2) Vasiliadis, H. M., Lesage, A., Adair, C., Wang, P. S., & Kessler, R. C. (2007). Do Canada and the United States differ in prevalence of depression and utilization of services?. *Psychiatric services (Washington, D.C.)*, 58(1), 63–71. <https://doi.org/10.1176/ps.2007.58.1.63>
- 3) Ringeisen, H., et. al. (2023). Mental and Substance Use Disorders Prevalence Study (MDPS): Findings Report. RTI International.
- 4) Zbozinek TD, et. al. Diagnostic overlap of generalized anxiety disorder and major depressive disorder in a primary care sample. *Depress Anxiety*. 2012 Dec;29(12):1065–71.
- 5) Forward-looking statements are subject to risks and assumptions. See "Cautionary Statement" on page 2 of this presentation.
- 6) Subject to receipt of all necessary regulatory approvals from all applicable governmental authorities, including, as applicable, the academic and scientific organizations with which Helus is working. There are multiple risk factors regarding the ability to successfully commercially scale a chemically synthesized process to obtain psilocin and other analogues. There is no assurance that timelines will be met. Anticipated timelines regarding drug development are based on reasonable assumptions informed by current knowledge and information available to Helus. Such statements are informed by, among other things, regulatory guidelines for developing a drug with timeline safety studies, proof of concept studies, and pivotal studies for new drug application submission and approval, and assumes the success of implementation and results of such studies on timelines indicated as possible by such guidelines, other industry examples, and Helus's development efforts to date.


## SLIDE 10

- 1) SPRAVATO® is a registered trademark of JOHNSON & JOHNSON Corporation, USA.
- 2) <https://www.grandviewresearch.com/industry-analysis/us-ketamine-clinics-market-report>
- 3) <https://neurostar.com/hcp/>, <https://www.brainsway.com/find-a-provider/>, <https://magventure.com/>
- 4) OSMIND is a registered trademark of OSMIND INC., USA.
- 5) Esketamine package insert
- 6) Hutton et al. (2023). Dosing transcranial magnetic stimulation in major depressive disorder: Relations between number of treatment sessions and effectiveness in a large patient registry. *Brain stimulation*, 16(5), 1510–1521. <https://doi.org/10.1016/j.brs.2023.10.001>
- 7) Thirthalli, J., Naik, S. S., & Kunigiri, G. (2020). Frequency and Duration of Course of ECT Sessions: An Appraisal of Recent Evidence. *Indian journal of psychological medicine*, 42(3), 207–218. [https://doi.org/10.4103/IJPSYM.IJPSYM\\_410\\_19](https://doi.org/10.4103/IJPSYM.IJPSYM_410_19)
- 8) HLP003 profile is illustrative and is subject to further validation in Phase 3 studies
- 9) No head-to-head comparisons have been made in any clinical trials that have been completed; results have been obtained from different trials with different designs, endpoints and patient populations; results may not be comparable.



# Appendix

# HLP003: Phase 2a Trial Design in MDD<sup>1,2,3</sup>



**Phase 1:** Single ascending dose study (1-10 mg), n=12

**Phase 2a:** RCT in MDD patients (12 mg, n=24; 16 mg, n=12)

## Key Inclusion Criteria:

- ✓ Moderate to severe MDD (MADRS  $\geq$  21)
- ✓ Inadequate response to antidepressant medication

## Primary Endpoint:

- ✓ Reduction in depression symptoms (change in MADRS score) at Week 3 after a single dose<sup>1</sup> vs. placebo

### Notes:

- 1) Patients allowed to remain on stable doses of antidepressant medications.
- 2) Primary efficacy assessed at Week 3; Optional 12 week follow up to assess durability of effects.
- 3) Forward looking statements are subject to risks and assumptions. See "Cautionary Statement" on page 2 of this presentation. There is no assurance that timelines will be met. Anticipated timelines regarding drug development are based on reasonable assumptions informed by current knowledge and information available to Helus. Such statements are informed by, among other things, regulatory guidelines for developing a drug with timeline safety studies, proof of concept studies, and pivotal studies for new drug application submission and approval, and assumes the success of implementation and results of such studies on timelines indicated as possible by such guidelines, other industry examples, and Helus's development efforts to date.

# Positive Phase 2 HLP003 Results in MDD

Rapid onset of effect

Improvement in symptoms after single dose

Large improvements in symptoms

At 3 weeks: 12 mg better than placebo on MADRS by 14.1 points ( $p=0.0001$ ), Cohen's  $d=2.31$   
16 mg better than placebo on MADRS by 13 points ( $p=0.008$ ), Cohen's  $d=2.54$

Incremental benefit of 2<sup>nd</sup> dose

Average 5.8 points improvement on the MADRS after 2<sup>nd</sup> dose (12 mg)  
>75% response rates and up to 79% remission rates (12 mg) after a 2<sup>nd</sup> dose



Durable efficacy at 12 months

Benefit sustained to 12 months with 71% remission rate after 2 doses (16 mg)



Favorable safety and tolerability profile

All reported AEs mild to moderate; no AEs of suicidality

# Sustained Improvements in Depression Symptoms at 12 Months



# Response and Remission at 12 Months: 12 mg & 16 mg



# Favorable Safety Profile of HLP003

- No AEs were reported at the 12-month follow up.
- No reports of suicidal ideation or behavior or any long-term adverse sequelae.

In the short-term study:

- No SAEs and no participant discontinued the study due to an AE.
- Most common AEs were nausea, elevated blood pressure and headache.
- Increases in blood pressure were transient and resolved without intervention.
- No clinically relevant changes in chemistry, hematology markers or ECG parameters.